Chroma was developing therapeutics for cancer and inflammatory disorders. The company built a pipeline of potential treatments using its expertise in chromatin biology and its novel intracellular accumulation technologies that included the ability to selectively target drugs to macrophages. The company sold rights to its lead development compound, an oral, once daily experimental cancer therapy, tosedostat, to CTI BioPharma. Chroma has partnered a number of preclinical assets with GlaxoSmithKline to develop macrophage-targeted compounds.